Bain Capital Life Sciences Investors, LLC Savara Inc Transaction History
Bain Capital Life Sciences Investors, LLC
- $370 Million
- Q4 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Savara Inc stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 14,565,457 shares of SVRA stock, worth $41.4 Million. This represents 12.07% of its overall portfolio holdings.
Number of Shares
14,565,457
Previous 14,565,457
-0.0%
Holding current value
$41.4 Million
Previous $61.8 Million
27.6%
% of portfolio
12.07%
Previous 11.08%
Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
140Shares Held
158MCall Options Held
55.6KPut Options Held
600-
Nea Management Company, LLC Timonium, MD24.5MShares$69.5 Million5.37% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$35.1 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$30.6 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$24.6 Million1.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.31MShares$23.6 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $324M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.